Literature DB >> 22487856

Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature.

Peter T Nelson1, Irina Alafuzoff, Eileen H Bigio, Constantin Bouras, Heiko Braak, Nigel J Cairns, Rudolph J Castellani, Barbara J Crain, Peter Davies, Kelly Del Tredici, Charles Duyckaerts, Matthew P Frosch, Vahram Haroutunian, Patrick R Hof, Christine M Hulette, Bradley T Hyman, Takeshi Iwatsubo, Kurt A Jellinger, Gregory A Jicha, Enikö Kövari, Walter A Kukull, James B Leverenz, Seth Love, Ian R Mackenzie, David M Mann, Eliezer Masliah, Ann C McKee, Thomas J Montine, John C Morris, Julie A Schneider, Joshua A Sonnen, Dietmar R Thal, John Q Trojanowski, Juan C Troncoso, Thomas Wisniewski, Randall L Woltjer, Thomas G Beach.   

Abstract

Clinicopathologic correlation studies are critically important for the field of Alzheimer disease (AD) research. Studies on human subjects with autopsy confirmation entail numerous potential biases that affect both their general applicability and the validity of the correlations. Many sources of data variability can weaken the apparent correlation between cognitive status and AD neuropathologic changes. Indeed, most persons in advanced old age have significant non-AD brain lesions that may alter cognition independently of AD. Worldwide research efforts have evaluated thousands of human subjects to assess the causes of cognitive impairment in the elderly, and these studies have been interpreted in different ways. We review the literature focusing on the correlation of AD neuropathologic changes (i.e. β-amyloid plaques and neurofibrillary tangles) with cognitive impairment. We discuss the various patterns of brain changes that have been observed in elderly individuals to provide a perspective for understanding AD clinicopathologic correlation and conclude that evidence from many independent research centers strongly supports the existence of a specific disease, as defined by the presence of Aβ plaques and neurofibrillary tangles. Although Aβ plaques may play a key role in AD pathogenesis, the severity of cognitive impairment correlates best with the burden of neocortical neurofibrillary tangles.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22487856      PMCID: PMC3560290          DOI: 10.1097/NEN.0b013e31825018f7

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  341 in total

1.  Validation of the neuropathologic criteria of the third consortium for dementia with Lewy bodies for prospectively diagnosed cases.

Authors:  Hiroshige Fujishiro; Tanis J Ferman; Bradley F Boeve; Glenn E Smith; Neill R Graff-Radford; Ryan J Uitti; Zbigniew K Wszolek; David S Knopman; Ronald C Petersen; Joseph E Parisi; Dennis W Dickson
Journal:  J Neuropathol Exp Neurol       Date:  2008-07       Impact factor: 3.685

2.  The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects.

Authors:  G Blessed; B E Tomlinson; M Roth
Journal:  Br J Psychiatry       Date:  1968-07       Impact factor: 9.319

3.  About the presence of paired helical filaments in dystrophic neurites participating in the plaque formation.

Authors:  M Barcikowska; H M Wisniewski; C Bancher; I Grundke-Iqbal
Journal:  Acta Neuropathol       Date:  1989       Impact factor: 17.088

4.  Cerebral infarctions and the likelihood of dementia from Alzheimer disease pathology.

Authors:  J A Schneider; R S Wilson; J L Bienias; D A Evans; D A Bennett
Journal:  Neurology       Date:  2004-04-13       Impact factor: 9.910

5.  Autopsy diagnoses of malignant neoplasms: how often are clinical diagnoses incorrect?

Authors:  E C Burton; D A Troxclair; W P Newman
Journal:  JAMA       Date:  1998-10-14       Impact factor: 56.272

6.  No increased incidence of Alzheimer's disease in elderly schizophrenics.

Authors:  K A Jellinger; E Gabriel
Journal:  Acta Neuropathol       Date:  1999-02       Impact factor: 17.088

7.  Early and widespread cholinergic losses differentiate dementia with Lewy bodies from Alzheimer disease.

Authors:  Pietro Tiraboschi; Larry A Hansen; Michael Alford; Annette Merdes; Eliezer Masliah; Leon J Thal; Jody Corey-Bloom
Journal:  Arch Gen Psychiatry       Date:  2002-10

8.  The neuropathology of older persons with and without dementia from community versus clinic cohorts.

Authors:  Julie A Schneider; Neelum T Aggarwal; Lisa Barnes; Patricia Boyle; David A Bennett
Journal:  J Alzheimers Dis       Date:  2009       Impact factor: 4.472

9.  Correlations between mental state and quantitative neuropathology in the Vienna Longitudinal Study on Dementia.

Authors:  C Bancher; K Jellinger; H Lassmann; P Fischer; F Leblhuber
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1996       Impact factor: 5.270

10.  Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry.

Authors:  Heiko Braak; Irina Alafuzoff; Thomas Arzberger; Hans Kretzschmar; Kelly Del Tredici
Journal:  Acta Neuropathol       Date:  2006-08-12       Impact factor: 17.088

View more
  695 in total

1.  PAK inactivation impairs social recognition in 3xTg-AD Mice without increasing brain deposition of tau and Aβ.

Authors:  Dany Arsenault; Alexandre Dal-Pan; Cyntia Tremblay; David A Bennett; Matthieu J Guitton; Yves De Koninck; Susumu Tonegawa; Frédéric Calon
Journal:  J Neurosci       Date:  2013-06-26       Impact factor: 6.167

2.  Levels of tau protein in plasma are associated with neurodegeneration and cognitive function in a population-based elderly cohort.

Authors:  Jeffrey L Dage; Alexandra M V Wennberg; David C Airey; Clinton E Hagen; David S Knopman; Mary M Machulda; Rosebud O Roberts; Clifford R Jack; Ronald C Petersen; Michelle M Mielke
Journal:  Alzheimers Dement       Date:  2016-07-18       Impact factor: 21.566

3.  MA-[D-Leu-4]-OB3, a small molecule synthetic peptide leptin mimetic, improves episodic memory, and reduces serum levels of tumor necrosis factor-alpha and neurodegeneration in mouse models of Type 1 and Type 2 Diabetes Mellitus.

Authors:  Zall Hirschstein; Gautam Reddy Vanga; Guirong Wang; Zachary M Novakovic; Patricia Grasso
Journal:  Biochim Biophys Acta Gen Subj       Date:  2020-07-29       Impact factor: 3.770

Review 4.  Challenges of multimorbidity of the aging brain: a critical update.

Authors:  Kurt A Jellinger; Johannes Attems
Journal:  J Neural Transm (Vienna)       Date:  2014-08-05       Impact factor: 3.575

5.  Altered temporal lobe white matter lipid ion profiles in an experimental model of sporadic Alzheimer's disease.

Authors:  Ming Tong; Raiane Leão; Gina V Vimbela; Emine B Yalcin; Jared Kay; Alexander Krotow; Suzanne M de la Monte
Journal:  Mol Cell Neurosci       Date:  2017-04-21       Impact factor: 4.314

Review 6.  Targeting Tumor Necrosis Factor Alpha for Alzheimer's Disease.

Authors:  Boris Decourt; Debomoy K Lahiri; Marwan N Sabbagh
Journal:  Curr Alzheimer Res       Date:  2017       Impact factor: 3.498

7.  Nonparametric discrete survival function estimation with uncertain endpoints using an internal validation subsample.

Authors:  Jarcy Zee; Sharon X Xie
Journal:  Biometrics       Date:  2015-04-27       Impact factor: 2.571

8.  Taxifolin prevents β-amyloid-induced impairments of synaptic formation and deficits of memory via the inhibition of cytosolic phospholipase A2/prostaglandin E2 content.

Authors:  Yuanyuan Wang; Qinwen Wang; Xiaoming Bao; Yanfei Ding; Jieyi Shentu; Wei Cui; Xiaowei Chen; Xiaofei Wei; Shujun Xu
Journal:  Metab Brain Dis       Date:  2018-03-14       Impact factor: 3.584

9.  Vascular risk factors are associated with longitudinal changes in cerebrospinal fluid tau markers and cognition in preclinical Alzheimer's disease.

Authors:  Isabelle Bos; Stephanie J B Vos; Suzanne E Schindler; Jason Hassenstab; Chengjie Xiong; Elizabeth Grant; Frans Verhey; John C Morris; Pieter Jelle Visser; Anne M Fagan
Journal:  Alzheimers Dement       Date:  2019-08-01       Impact factor: 21.566

10.  Tau Accumulation in Clinically Normal Older Adults Is Associated with Hippocampal Hyperactivity.

Authors:  Willem Huijbers; Aaron P Schultz; Kathryn V Papp; Molly R LaPoint; Bernard Hanseeuw; Jasmeer P Chhatwal; Trey Hedden; Keith A Johnson; Reisa A Sperling
Journal:  J Neurosci       Date:  2018-11-27       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.